Bioverativ controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile1 entries
2023
Settlement of insider-trading-related litigation
Bioverativ and Sanofi settled a case alleging that Bioverativ's board assisted a hedge-fund manager in profiting from nonpublic information about Sanofi's planned acquisition of Bioverativ. The reported settlement amount was $84 million.